MPS Q2 FY27 Results: Consolidated Net Profit ₹52.10 Crore on Total Income of ₹227 Crore
- Earnings
- Research and education solutions
Reviewed byKeshav SehgalBlacklitt Research
MPS reported consolidated total income of ₹226.53 crore and net profit of ₹52.10 crore for the quarter ended 30 Sep 2026. On a standalone basis, total income was ₹128.50 crore and net profit was ₹37.59 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹226.53 crore, up 15.2% YoY and down 0.3% QoQ.
- Net profit: ₹52.10 crore, down 6.0% YoY and up 3.4% QoQ.
- Finance costs: ₹0.64 crore, against ₹0.29 crore a year earlier and ₹1.13 crore in the preceding quarter.
Standalone
The company on its own, without its subsidiaries
- Total income: ₹128.50 crore, up 14.6% YoY and down 1.7% QoQ.
- Net profit and EPS: ₹37.59 crore, up 24.4% YoY and down 8.2% QoQ; basic EPS ₹22.15.
- Other income: ₹2.14 crore, against ₹0.91 crore a year earlier and ₹6.33 crore in the preceding quarter.
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 227 | 197 | +15.2% | 227 | -0.3% | |
| Revenue from operations | 224 | 194 | +15.4% | 224 | 0.0% |
| 52 | 55 | -6.0% | 50 | +3.4% | |
| Profit before tax | 69 | 69 | +0.3% | 70 | -0.6% |
| Finance costs | 1 | 0 | +120.7% | 1 | -43.4% |
| Depreciation | 9 | 6 | +51.3% | 9 | +3.6% |
| Net profit margin | 23.00% | 28.19% | -5.19 pp | 22.18% | +0.82 pp |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Consolidated total income rose 15.2% on the year to ₹226.53 crore, while net profit fell 6.0% to ₹52.10 crore from ₹55.45 crore. Profit before tax was ₹69.40 crore, against ₹69.17 crore a year earlier, a rise of 0.3%.
The year-earlier quarter includes an exceptional item that the filing names: a write-back of ₹13.25 crore relating to the Liberate Group acquisition, recognised under exceptional items (net) in the quarter ended 30 Sep 2025. The filing says there is no exceptional item in the quarter ended 30 Sep 2026.
Depreciation rose to ₹9.23 crore from ₹6.10 crore a year earlier, and finance costs to ₹0.64 crore from ₹0.29 crore. Finance costs were ₹1.13 crore in the quarter ended 30 Jun 2026.
The net profit margin on total income was 23.00%, against 28.19% a year earlier and 22.18% in the preceding quarter.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 129 | 112 | +14.6% | 131 | -1.7% | |
| Revenue from operations | 126 | 111 | +13.6% | 124 | +1.6% |
| Other income | 2 | 1 | +135.2% | 6 | -66.2% |
| 38 | 30 | +24.4% | 41 | -8.2% | |
| Profit before tax | 51 | 42 | +22.3% | 56 | -8.6% |
| Finance costs | 1 | 0 | +144.0% | 1 | -44.5% |
| Depreciation | 4 | 3 | +41.6% | 3 | +10.6% |
| Tax expense | 14 | 12 | +16.7% | 15 | -9.8% |
| Net profit margin | 29.25% | 26.95% | +2.31 pp | 31.34% | -2.09 pp |
| EPS, basic (₹) | 22.15 | 17.81 | +24.4% | 24.14 | -8.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 24.4% to ₹37.59 crore, faster than total income, which rose 14.6% to ₹128.50 crore. Profit before tax was ₹51.28 crore, against ₹41.94 crore a year earlier, up 22.3%.
Revenue from operations rose 13.6% to ₹126.36 crore from ₹111.20 crore a year earlier. Other income rose 135.2%, from ₹0.91 crore to ₹2.14 crore.
Within revenue from operations, Research solutions was ₹95.95 crore in the quarter, up 8.4% from ₹88.55 crore in the quarter ended 30 Jun 2026. Education solutions was ₹30.41 crore, down 15.1% from ₹35.81 crore.
Standalone net profit fell 8.2% from the preceding quarter, more than total income (down 1.7%). Basic EPS was ₹22.15, against ₹24.14 in the quarter ended 30 Jun 2026 and ₹17.81 a year earlier.
The standalone results include ₹3.04 crore of dividend income from TOPSIM GmbH, a wholly owned subsidiary, recognised under other income for the half year ended 30 Sep 2026.
The filing says the company completed the acquisition of Unbound Medicine, Inc., USA, on 9 Feb 2026 for USD 16.50 million (about ₹149 crore). The consideration was revised to USD 15.74 million (about ₹142 crore) after net working capital adjustments. Provisional goodwill of ₹126.07 crore has been recognised, and the purchase price allocation will be finalised within 12 months of the acquisition date.
Inference
The board approved the re-appointment of Divya Verma as a Non-Executive Independent Director for a second term of five years, from 24 Jan 2027 to 23 Jan 2032. The appointment is subject to a special resolution of shareholders, to be sought through a postal ballot.
The scheme of amalgamation of ADI BPO Services Limited with the company was approved by equity shareholders and unsecured creditors at meetings held on 22 Aug 2026. The second motion petition is listed before the NCLT on 4 Nov 2026, and the results give no effect to the scheme pending its sanction. When the NCLT will sanction the scheme is not known from the filing.
The board also approved amendments to the code of conduct for trading in the company's securities and to the code of practices for fair disclosure of unpublished price sensitive information.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
